Trastuzumab basic Characters
|Melt Point:||61-71 °C|
|Storage Temp:||2-8 °C|
Trastuzumab (180288-69-1) usage in steroids cycle
Trastuzumab (CAS 180288-69-1), trade name is Herceptin.
Trastuzumab is given through an infusion into vein (intravenous, IV). The first dose is given over 90 minutes. If well-tolerated subsequent maintenance doses may be given over 30 minutes.
The amount of Trastuzumab (180288-69-1) that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.
Warning on Trastuzumab
A serious but uncommon side effect of Trastuzumab can be interference with the pumping action of the heart. The incidence of heart problems (heart failure) increase in people with heart disease or other risk factors such as radiation to the chest, advancing age, and use of other heart-toxic drugs (such as doxorubicin and cyclophosphamide). Your doctor may check your heart function before you may take any Trastuzumab and will monitor your heart closely during your treatment. Trastuzumab (180288-69-1) may be discontinued if symptoms of heart failure appear.
Monoclonal antibodies are a relatively new type of “targeted” cancer therapy. Antibodies are part of the immune system. Normally, the body creates antibodies in response to an antigen (such as a protein in a germ) entering the body. The antibodies attach to the antigen in order to mark it for destruction by the body’s immune system. In the laboratory, scientists analyze specific antigens on the surface of cancer cells (target) to determine a protein to match the antigen. Then, using animal and human proteins, scientists work to create a special antibody that will attach to the target antigen. Antibodies will attach to matching antigens like a key fits a lock. This technology allows treatment to target specific cells, causing less toxicity to healthy cells. Monoclonal antibody therapy can be done only for cancers in which antigens (and the respective antibodies) have been identified.
Trastuzumab works by targeting the HER2/neu receptor on cancer cells. The HER2 gene produces a protein receptor on the cell surface that signals normal cell growth by telling the cell to divide and multiply. Some cancerous breast tissue has too much HER2 (HER2/neu overexpression), triggering the cells to divide and multiply very rapidly. Trastuzumab (180288-69-1) attaches to the HER2 receptors to prevent cells from multiplying, preventing further cancer growth and slowing cancer progression. It may also work by stimulating an immune mechanism.
How to buy Trastuzumab from AASraw
1.To contact us by our email inquiry system,or online skypecustomer service representative(CSR).
2.To provide us your inquired quantity and address.
3.Our CSR will provide you the quotation, payment term, tracking number, delivery ways and estimated arrival date(ETA).
4.Payment done and the goods will be sent out in 12 hours(For order within 10kg).
5.Goods received and give comments.
PRECAUTION AND DISCLAIMER:
This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.